The appetite for risk in orthopedic medical device companies evolves dramatically with their size—reflecting changes in resources, priorities, and stakeholder pressures.In my last startup, the CEO hammered it home: our only real advantage over the Big Orthos was the freedom to take extreme risks every single week.
Here's how that appetite shifts as companies grow:
1. Startup Phase (~5 employees, zero to minimal sales)
Pure survival mode. With no revenue cushion, bold innovation is non-negotiable. Tiny teams chase moonshot implants or instruments, swinging for high-risk/high-reward breakthrough...
